Trial Profile

A phase I study of F230 for the Treatment of Pulmonary Arterial Hypertension

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 25 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs F 230 (Primary)
Indications Pulmonary arterial hypertension
Focus Adverse reactions

Most Recent Events

13 Aug 2024 According to a Gyre Therapeutics media release, the company expects to initiate this trial in 2025.
03 Jun 2024 New trial record
30 May 2024 According to a Gyre Therapeutics media release, the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for F230 tablets, for the treatment of pulmonary arterial hypertension.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com